SEP 03, 2015 7:30 AM PDT

Keynote: Using New Technology to Control Healthcare Associated Disease

Presented at: Microbiology
Speaker

Abstract

Control of infection from methicillin resistant Staphylococcus aureus (MRSA) has been a healthcare focus for more than 50 years. One of the reasons that active surveillance testing (AST) for MRSA is expected to be effective is that the greatest risk factor for developing clinical disease is to first become colonized in the nares with MRSA. Critically, persons who are either colonized or infected with MRSA are equally likely to have their skin and surrounding environment contaminated with this organism. Therefore, strategies to limit transmission that consider both colonized and infected persons are most likely to be successful at reducing disease. For healthcare organizations that do not have MRSA well controlled, the recent SHEA compendium recommends AST as one method to identify carriers and reduce spread to new patients. NorthShore University HealthSystem began an AST program for MRSA control on August 1, 2005 and realized a 70% reduction in clinical MRSA disease. Careful monitoring of patient benefit and cost reduction associated with lowered healthcare associated infection justifies the program to hospital administration. In 10 years the MRSA control program led to a net healthcare benefit of $20 million in reduced cost, with more than 1,000 infections avoided and 180 prevented deaths. Another key healthcare associated disease, particularly in Europe and the United States, is Clostridium difficile infection (CDI). In 2001 there were 5 CDI cases for every 1,000 discharges from US hospitals and it is estimated that by 2013 the rate had nearly tripled. New nucleic acid amplification tests (NAATs) have doubled the sensitivity of past enzyme immunoassays (EIAs) and are now recommended as the superior diagnostic approach by the American Society for Gastroenterology. Argument remains over whether to just use the NAAT approach as a single assay method or implement a diagnostic algorithm including some form of initial EIA screening.


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
AUG 24, 2022 7:00 AM PDT
AUG 24, 2022 7:00 AM PDT
Date: August 24, 2022 Time: 7:00am (PDT), 10:00pm (EDT), 4:00pm (CEST) Light field microscopy was first introduced in 2006, and allows users to capture the 4D light field within the microsco...
OCT 05, 2022 9:00 AM PDT
C.E. CREDITS
OCT 05, 2022 9:00 AM PDT
Date: October 05, 2022 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CEST) Candida auris is a multi-drug resistant yeast that continues to be a global threat for infection and transmission in h...
SEP 29, 2022 8:00 AM PDT
SEP 29, 2022 8:00 AM PDT
Date: September 29, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Adeno-associated virus (AAV) is one of the most widely used delivery vehicles in gene therapy. To ensure the safety...
SEP 03, 2015 7:30 AM PDT

Keynote: Using New Technology to Control Healthcare Associated Disease

Presented at: Microbiology


Show Resources
Loading Comments...
Show Resources
Attendees